Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes

BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin‐9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in t...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Am Heart Assoc
Huvudupphovsmän: Gencer, Baris, Koskinas, Konstantinos C., Räber, Lorenz, Karagiannis, Alexios, Nanchen, David, Auer, Reto, Carballo, David, Carballo, Sebastian, Klingenberg, Roland, Heg, Dik, Matter, Christian M., Lüscher, Thomas F., Rodondi, Nicolas, Mach, François, Windecker, Stephan
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5721754/
https://ncbi.nlm.nih.gov/pubmed/29122809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006537
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk